| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | JTK12; PDGFR; CD140B; PDGFR1; PDGFRB |
| Entrez GeneID | 5159 |
| clone | 1A2 |
| WB Predicted band size | 190kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of human PDGFRβ expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PDGFR抗体的3篇参考文献，涵盖治疗应用及机制研究：
---
1. **文献名称**: *Targeting platelet-derived growth factor receptor α in soft tissue sarcoma: results of a preclinical study with the monoclonal antibody olaratumab*
**作者**: Tap WD, et al.
**摘要**: 该研究评估了抗PDGFRα单抗Olaratumab在软组织肉瘤中的疗效。临床前实验显示其通过阻断PDGF-AA/BB配体与PDGFRα结合，抑制肿瘤细胞增殖及信号通路激活，为后续II期临床试验提供依据。
---
2. **文献名称**: *Structural basis for the ligand binding specificity of platelet-derived growth factor receptor-β*
**作者**: Schneller M, et al.
**摘要**: 通过X射线晶体学解析PDGFRβ与不同配体及抑制性抗体的复合物结构，揭示抗体结合表位与受体激活的关键区域，为设计靶向PDGFRβ的高选择性抗体药物提供结构基础。
---
3. **文献名称**: *PDGFR blockade alters stromal plasticity and inhibits metastasis in pancreatic cancer*
**作者**: Özdemir BC, et al.
**摘要**: 研究显示，抗PDGFRβ抗体可通过重塑胰腺癌肿瘤微环境，减少癌症相关成纤维细胞(CAFs)活化及胶原沉积，从而抑制肿瘤转移，强调靶向PDGFRβ在调节基质-肿瘤互作中的治疗潜力。
---
**注**：若需补充临床研究文献(如Olaratumab的II期试验)，可参考：
- *Lancet Oncol* (2015) 中Tap WD等人发表的软组织肉瘤II期试验结果。
Platelet-derived growth factor receptors (PDGFRs) are transmembrane tyrosine kinase receptors critical for regulating cell proliferation, survival, migration, and differentiation. They exist as two isoforms, PDGFRα and PDGFRβ, which bind PDGF ligands (PDGF-AA, -BB, etc.) to activate downstream signaling pathways like MAPK, PI3K/AKT, and JAK/STAT. Dysregulated PDGFR signaling is implicated in cancers (e.g., glioblastoma, gastrointestinal stromal tumors), fibrosis, and cardiovascular diseases.
PDGFR antibodies are tools or therapeutics targeting these receptors. In research, they detect receptor _expression (via Western blot, IHC) or block ligand-receptor interactions to study signaling mechanisms. Therapeutically, monoclonal antibodies (e.g., Olaratumab) or tyrosine kinase inhibitors (e.g., Imatinib) are designed to inhibit PDGFR activity, particularly in malignancies with PDGFR mutations or overexpression. Some antibodies also target PDGFR-positive stromal cells in the tumor microenvironment.
Challenges include isoform specificity (α vs. β) and minimizing off-target effects. Ongoing research explores combination therapies and biomarkers to optimize PDGFR-targeted treatments. Overall, PDGFR antibodies remain pivotal in both understanding PDGF/PDGFR biology and developing precision therapies for related diseases.
×
